Tags : OPKO

PharmaShots’ Key Highlights of Fourth Quarter 2019

1. Pfizer Launched its Zirabev (biosimilar, bevacizumab) in the US by the year end 2019 Date – Oct 01, 2019 Product – Zirabev (biosimilar, bevacizumab) The biosimilar was launched in the US on Dec 31, 2019 following the settlement between Genentech and Pfizer granting all global rights of the product to the Pfizer. In Sept […]Read More

PharmaShots Weekly Snapshot (October 21-25, 2019)

1. Urology San Antonio Collaborates with Anixa Biosciences on Ccheck Prostate Cancer Study Published: Oct 25, 2019 | Tags: Urology San Antonio, Collaborates, Anixa Biosciences, Ccheck, Prostate Cancer Study 2. NHS England Signs an Agreement with Vertex to Access All Licensed Cystic Fibrosis Therapies Published: Oct 24, 2019 | Tags: NHS England, Signs, Agreement, Vertex, Access, Licensed, […]Read More

Pfizer and OPKO Reports Results of Somatrogon in P-III Study

Shots: The P-III study involves assessing of Somatrogon (qw) vs Genotropin (somatropin,qd) for injection, in 224 pre-pubertal, treatment-naive children in a ratio (1:1) with growth hormone deficiency across 20 countries The P-III study resulted in meeting its 1EPs of non-inferiority to somatropin with respect to height velocity at 12 mos. of treatment, least-square mean (10.12 […]Read More